文献速递泌尿男性生殖肿瘤

B7-H4与肌层浸润性膀胱癌临床结局及免疫治疗获益的相关性

B7-H4 correlates with clinical outcome and immunotherapeutic benefit in muscle-invasive bladder cancer.
PubMed 文献 · Eur J Cancer · 2022-06-16

研究纳入TCGA数据库391例和中山医院122例肌层浸润性膀胱癌患者,并以IMvigor210队列270例评估PD-L1抑制剂反应。B7-H4高表达者总生存和无复发生存较差,但对顺铂化疗和抗PD-L1免疫治疗有显著临床获益;B7-H4高表达且TMB高亚组从PD-L1阻断中获益最大。

要点

  • B7-H4高表达肌层浸润性膀胱癌患者总生存和无复发生存较差。
  • B7-H4高表达者对顺铂化疗和抗PD-L1免疫治疗有显著临床获益。
  • B7-H4高表达且TMB高亚组从PD-L1阻断中获益最大。

核心结论

  • B7-H4高表达患者虽临床结局较差,但对化疗和免疫治疗有更优反应性。
  • B7-H4分层可与TMB协同识别从免疫治疗中获益最大的患者。
  • 作者认为B7-H4作为伴随预测标志物的临床探索可帮助临床医生为患者选择合适治疗药物。

研究设计与样本

  • 研究纳入TCGA数据库391例和中山医院122例肌层浸润性膀胱癌患者。
  • 以IMvigor210队列270例患者评估PD-L1抑制剂反应。
  • 采用Kaplan-Meier生存分析和多因素分析在三个队列中评估临床结局。
  • 基于免疫组化、MCP-counter工具和全外显子测序分析B7-H4表达与免疫微环境及基因组改变的相关性。

主要发现

  • B7-H4高表达肌层浸润性膀胱癌患者总生存和无复发生存较差。
  • B7-H4高表达患者对顺铂化疗和抗PD-L1免疫治疗观察到显著临床获益。
  • B7-H4与肿瘤突变负荷(TMB)呈正相关,B7-H4高表达且TMB高亚组从PD-L1阻断中获益最大。
  • B7-H4高表达亚组以非炎症免疫微环境和细胞周期相关基因改变为特征。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: B7-H4, a sibling to PD-L1 in B7 family, has been reported to be a novel immune checkpoint that is prevalent among non-inflamed tumors. Herein, we attempt to explore the potential of B7-H4 in survival prediction and therapeutic guidance in muscle-invasive bladder cancer (MIBC) patients. METHODS: This study included 391 patients from The Cancer Genome Atlas (TCGA) database and 122 patients from Zhongshan (ZS) Hospital. The evaluation of response to PD-L1 inhibitors was based on 270 patients in IMvigor210 cohort. Kaplan-Meier survival and multivariate analyses were performed to assess clinical outcomes in three cohorts. The correlation of B7-H4 expression with immune contexture and genomic alterations was analyzed based on immunohistochemistry, Microenvironment Cell Populations-counter (MCP-counter) tool, and whole-exome sequencing. RESULTS: MIBC patients with the high level of B7-H4 expression (B7-H4high) were found to possess an inferior overall and recurrence-free survival. Nonetheless, substantial clinical benefits of cisplatin-based chemotherapy and anti-PD-L1 immunotherapy were observed in these patients. After identifying a positive correlation between B7-H4 and tumor mutation burden (TMB), clinical benefits in B7-H4high TMBhigh subgroup were found to be the most upon PD-L1 blockade. Further studies revealed that B7-H4high subgroup was featured by non-inflamed immune contexture and cell cycle-related gene alterations. CONCLUSIONS: Despite adverse clinical outcomes, B7-H4high patients possessed superior responsiveness to chemotherapy and immunotherapy. B7-H4 stratification could also synergize with TMB to pinpoint the patients who benefited most from immunotherapy. The clinical exploration of B7-H4 as a companion predictor could allow clinicians to direct proper therapeutic agents to patients.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Liu Z, Jin K, Zeng H, et al. B7-H4 correlates with clinical outcome and immunotherapeutic benefit in muscle-invasive bladder cancer. Eur J Cancer. 2022. PMID: 35717821. doi:10.1016/j.ejca.2022.05.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。